资讯

《Rheumatology International》:Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple Sclerosis-like syndrome: a systematic review 【字体: 大 中 小 】 时间:2025年06月04日 ...
本研究揭示了LKB1缺失通过CRTC2依赖性信号通路驱动致病性TH17细胞分化,促进IL-17依赖性胃肠道息肉生长的分子机制。研究人员通过基因工程小鼠模型和单细胞测序技术,发现靶向CRTC2-IL-17信号轴可有效抑制Peutz-Jeghers综合征模型息肉发展,为LKB1突变相关肿瘤的免疫治疗提供新靶点。
两篇Cell齐发:抗感染的细胞因子IL-17还作用于大脑,引发焦虑或促进社交. 来源:生物世界 2025-04-11 11:13. 这两项研究共同表明,免疫系统,甚至单个 ...
Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...
本研究是首个银屑病领域在il-17单抗应答不佳人群中开展转药治疗的随机、双盲、活性对照的iii期临床研究,在il-17单抗继续治疗对照下,证明匹康奇 ...
通过对修复相关的淋巴细胞进行无偏见的分析,这些作者发现了17型淋巴细胞的异质性群体的富集。缺少RORγt+细胞的纯合子Rorgt-EGFP小鼠(下称GFI-KI小 ...
Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis ...
Aging:揭示促炎性细胞因子IL-17在骨关节炎发病机制中的关键作用. 来源:生物谷原创 2024-02-24 10:56. 这项研究中,研究人员利用来自健康供体和骨关节 ...
IL-17A, commonly referred to as IL-17, is the founding member of the IL-17 family, which consists of six ligands, A–F. IL-17F shares 50% sequence homology with IL-17A and has similar but less ...
礼来IL-23单抗头对头击败乌司奴单抗。 2024年10月14日,礼来更新了旗下IL-23单抗mirikizumab(米吉珠单抗)治疗中重度克罗恩病(CD)患者的三期VIVID-1 ...
Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a ...
Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin-23 (IL-23) inhibitors. However, IL-23 inhibitors were often favored due to their safety profile and ...